株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

展開再生医療:市場見通し 2016-2026年

Translational Regenerative Medicine - Market Prospects 2016-2026: Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?

発行 Visiongain Ltd 商品コード 209071
出版日 ページ情報 英文 285 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.86円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
展開再生医療:市場見通し 2016-2026年 Translational Regenerative Medicine - Market Prospects 2016-2026: Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?
出版日: 2016年01月29日 ページ情報: 英文 285 Pages
概要

当レポートでは、展開再生医療市場の動向、市場の機会、収益予測、各分野の研究開発と事業開発、2次市場の動向などをまとめ、お届けいたします。

第1章 調査概要

第2章 展開再生医療のイントロダクション

  • 展開再生医療とは?
  • 展開再生医療:市場分析
    • 幹細胞治療:市場性のある差別化・専門可
    • 組織エンジニアリング:治療目的のインビトロマニピュレーション
    • 遺伝子治療
  • 再生医療のその他のアプローチ
  • 再生医療に対する法規制
    • 欧州における法規制
    • 米国における法規制
  • 治験の段階
  • 市場定義

第3章 展開再生医療市場

  • 世界の展開再生医療:市場概要
  • 世界の展開再生医療市場
  • 世界の展開再生医療:市場予測

第4章 幹細胞治療:主な用途

  • 世界の幹細胞治療市場
  • 幹細胞治療:世界市場の予測
  • AlloStem (AlloSource)
  • Osteocel Plus (NuVasive)
  • Trinity ELITE および Trinity Evolution (Orthofix)
  • PureGen (AlphaTec Spine)
  • その他の認可済み幹細胞治療製品
  • 幹細胞治療の開発パイプライン
  • 幹細胞治療市場:促進因子・阻害因子

第5章 組織エンジニアリング治療:主な用途

  • 世界の組織エンジニアリング治療市場
  • 組織エンジニアリング治療:世界市場の予測
  • 創傷修復・創傷治癒における組織エンジニアリング
  • 軟骨修復における組織エンジニアリング
  • その他の利用可能な組織エンジニアリング治療
  • 組織エンジニアリング:開発パイプライン
  • 臓器移植・組織エンジニアリングの将来見通し
  • 組織エンジニアリング製品市場:促進因子・阻害因子

第6章 遺伝子治療:主な用途

  • 世界の遺伝子治療市場
  • 遺伝子治療:世界市場の予測
  • 現在利用可能な遺伝子治療製品
  • 遺伝子治療の開発パイプライン
  • 遺伝子治療市場:促進因子・阻害因子

第7章 展開再生医療の主要国市場

  • 展開再生医療市場:地域別
  • 主要国市場:予測
  • 地域の展開再生医療市場:分析と予測
  • 米国:最大の展開再生医療市場
  • 欧州:断片化した展開再生医療市場
  • アジア太平洋:迅速な製品商品化を助ける柔軟な規制環境
  • その他

第8章 展開再生医療市場における主要企業

  • 展開再生医療:革新の温床
  • Alphatec Spine
  • Anterogen
  • Athersys
  • Avita Medical
  • AxoGen
  • Medipost
  • Mesoblast
  • NuVasive
  • Ocata Therapeutics
  • Organogenesis
  • Osiris Therapeutics
  • Pharmicell
  • Regenerys
  • TiGenix
  • UniQure

第9章 世界の展開再生医療市場の定性分析

  • 市場影響因子
  • SWOT分析
  • ポーターのファイブフォース分析

第10章 調査インタビュー

  • インタビュー:Cynthia Bamdad博士(PhD, Minerva Biotechnologies のCEO)
  • インタビュー:Yael Margolin博士(Gamida Cell Ltd. のCEO)

第11章 結論

  • 現在の市況・市場予測の概要
  • 主要な再生医療区分
  • 主要地域
  • 将来の展望
  • 将来の市場成長に重要なR&Dパイプライン製品
  • 将来予測

第12章 用語集

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0087

What can be expected from the Translational Regenerative Medicine market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 285-page report provides 170 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of translational regenerative medicine market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2026? Our study forecasts revenues in the following Translational regenerative medicine submarkets:

  • Stem Cell Therapies
  • Tissue Engineering
  • Gene Therapies

image1

See revenue forecasts for some the leading products in the market

How will leading drug perform to 2026? Our study forecasts revenues for a number of leading products in the translational regenerative medicine market including:

  • Osteocel Plus
  • Trinity ELITE
  • TEMCELL /Prochymal
  • Apligraf
  • Dermagraft
  • ReCell
  • Neovasculgen
  • Glybera (alipogene tiparvovec)
  • IMLYGIC (talimogene laherparepvec)

See revenue forecasts for the leading regional markets

How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:

  • US
  • Europe
  • Asia-Pacific
  • Rest of World

Leading companies and potential for market growth

Overall revenue for the Translational Regenerative Medicine market will reach $12.1bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of 16 leading companies, including these:

  • Alphatec Spine
  • Anterogen
  • Athersys
  • Avita Medical
  • AxoGen
  • Medipost
  • Mesoblast
  • NuVasive
  • Ocata Therapeutics
  • Organogenesis
  • Osiris Therapeutics
  • Pharmicell
  • Regenersys
  • TiGenix
  • UniQure
  • Vericel Corporation

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance over the past 5 years
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect translational regenerative medicine industry?

Our new report discusses issues and events affecting the translational regenerative medicine market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Changing regulatory landscape challenging new entrants and major market players alike
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Translational Regenerative Medicine: Market Prospects 2016-2026 report helps you

In summary, our 285-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Translational Regenerative Medicine market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading translational regenerative medicine products in the following areas: stem cell therapies, tissue engineering and gene therapy.
  • Revenue forecasts to 2026 for 9 of the leading products in the Translational Regenerative Medicine market - discover prospects for leading translational regenerative medicine products including: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymal, Apligraf, Dermagraft, ReCell, Neovasculgen, Glybera (alipogene tiparvovec) and IMLYGIC (talimogene laherparepvec)
  • Revenue forecasts to 2026 for one leading national market and two leading regional markets - US, Europe, Asia-Pacific and Rest of World
  • Assessment of 16 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the translational regenerative medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

Table of Contents

1. Report Overview

  • 1.1 Global Translational Regenerative Medicine: Market Overview
  • 1.2 Global Translational Regenerative Medicine Market Definition and Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered By This Analytical Report
  • 1.6 Who Is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction To Translational Regenerative Medicine

  • 2.1 What Is Regenerative Medicine?
    • 2.1.1 Translational Regenerative Medicine - From Bench to Bedside
  • 2.2 Translational Regenerative Medicine - Market Breakdown
    • 2.2.1 Stem Cell Therapy - Marketable Differentiation And Specialisation
    • 2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray
    • 2.2.1.2 Classifying Stem Cells by Potency
    • 2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
    • 2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
    • 2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
    • 2.2.2 Tissue Engineering - In Vitro Manipulation for Therapeutic Purposes
    • 2.2.3 Gene Therapies
    • 2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
  • 2.3 Other Approaches to Regenerative Medicine
    • 2.3.1 Small Molecules and Proteins - Scaffold-Based Delivery of Signalling Molecules
    • 2.3.2 Cosmetic Applications of Regenerative Medicine
  • 2.4 Regulation of Regenerative Medicine
    • 2.4.1 Regulation of Regenerative Medicine Products in Europe
    • 2.4.2 Regulation of Regenerative Medicine Products in the US
  • 2.5 The Phases of Clinical Trials
  • 2.6 Market Definition
    • 2.6.1 Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2016-2026

  • 3.1 Global Translational Regenerative Medicine: Market Overview
    • 3.1.1 Segments within the Global Translational Regenerative Medicine Market
  • 3.2 The Global Translational Regenerative Medicine Market in 2014 and 2015
  • 3.3 Global Translational Regenerative Medicine: Market Forecast 2016-2026
    • 3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
    • 3.3.2 Global Translational Regenerative Medicine Market - Changing Market Shares By Sector 2016-2026

4. Stem Cell Therapies: Leading Applications, 2016-2026

  • 4.1 The Global Market for Stem Cell Therapies, 2014 and 2015
    • 4.1.1 Stem Cell Therapies: Currently Available Therapies
    • 4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
    • 4.1.2.1 HSCT for the Treatment of Multiple Sclerosis - A Possible Cure?
    • 4.1.3 Stem Cell Orthobiologics
  • 4.2 Stem Cell Therapies: Global Market Forecast 2016-2026
  • 4.3 AlloStem (AlloSource)
  • 4.4 Osteocel Plus (NuVasive)
    • 4.4.1 Osteocel Plus: Sales Forecast 2016-2026
  • 4.5 Trinity ELITE and Trinity Evolution (Orthofix)
    • 4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2016-2026
  • 4.6 PureGen (AlphaTec Spine)
  • 4.7 Other Approved Stem Cell Therapy Products, 2015
    • 4.7.1 Cartistem (Medipost)
    • 4.7.2 Cupistem (Anterogen)
    • 4.7.3 Hearticellgram-AMI (Pharmicell)
    • 4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
    • 4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2016-2026
  • 4.8 Development Pipeline for Stem Cell Therapies, 2016-2026
    • 4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
      • 4.8.1.1 StemEx and NiCord (Gamida Cell)
        • 4.8.1.1.1 StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
      • 4.8.1.2 Copper Chelator Based Technology
      • 4.8.1.3 NiCord
        • 4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
        • 4.8.1.3.2 NAM Technology Platform
      • 4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
      • 4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
      • 4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
      • 4.8.1.7 Cx601 (TiGenix)
      • 4.8.1.8 Adipose-Derived Stem Cells (Cytori Therapeutics)
      • 4.8.1.9 Stempeucel (Stempeutics Research)
      • 4.8.1.10 C-Cure (Cardio3 BioSciences)
      • 4.8.1.11 Other Late-Stage Stem Cell Therapies
    • 4.8.2 Diabetes and Stem Cell Therapy
      • 4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
      • 4.8.2.2 VC-01 (ViaCyte Inc)
        • 4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
    • 4.8.3 Cardiovascular Disease and Stem Cell Therapy
      • 4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
      • 4.8.3.2 AMR-001 (Caladrius Biosciences)
      • 4.8.3.3 CAP-1002 (Capricor)
    • 4.8.4 Stem Cell Therapy in Cancer
      • 4.8.4.1 CLT-008 (Cellerant Therapeutics)
      • 4.8.4.2 OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy
    • 4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
      • 4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
        • 4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
      • 4.8.5.2 NSI-566 (Neuralstem)
      • 4.8.5.3 NSI-189 (Neuralstem)
      • 4.8.5.4 MultiStem (Athersys)
      • 4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
      • 4.8.5.6 ALD-401 (Cytomedix)
      • 4.8.5.7 ReN001 (ReNeuron)
    • 4.8.6 Stem Cell Therapy for Eye Diseases
      • 4.8.6.1 MA09-hRPE (Ocata Therapeutics)
      • 4.8.6.2 HuCNS-SC (StemCells Inc.)
      • 4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness
  • 4.9 Stem Cells Therapy Market: Drivers and Restraints 2016-2026

5. Tissue Engineering Therapies: Leading Applications, 2016-2026

  • 5.1 The Global Market for Tissue Engineered Therapies, 2014 and 2015
    • 5.1.1 Tissue Engineering Therapies: Currently Available Therapies
  • 5.2 Tissue Engineering Therapies: Global Market Forecast 2016-2026
  • 5.3 Tissue Engineering in Wound Repair and Healing
    • 5.3.1 Apligraf (Organogenesis)
      • 5.3.1.1 Apligraf: Historical Sales Analysis
      • 5.3.1.2 Apligraf: Sales Forecast 2016-2026
    • 5.3.2 BioDfence and BioDfactor (BioD)
    • 5.3.3 CureXcell (MacroCure)
    • 5.3.4 Dermagraft (Organogenesis)
    • 5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2016-2026
    • 5.3.5 Epicel (Vericel)
    • 5.3.6 Grafix (Osiris Therapeutics)
    • 5.3.7 MySkin and CyroSkin (Regenerys)
    • 5.3.8 ReCell (Avita Medical)
      • 5.3.8.1 ReCell (Avita Medical): Sales Forecast 2016-2026
  • 5.4 Tissue Engineering for Cartilage Repair
    • 5.4.1 Autologous Chondrocyte Implantation (ACI)
    • 5.4.2 Carticel (Vericel Corp.)
    • 5.4.3 ChondroCelect (TiGenix, Sobi Partners)
    • 5.4.4 DeNovo NT (Zimmer)
    • 5.4.5 MACI (Vericel Corp.)
  • 5.5 Other Available Tissue Engineering Therapies
    • 5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
    • 5.5.2 Gintuit (Organogenesis)
    • 5.5.3 LAVIV (azficel-T), (Fibrocell Science)
    • 5.5.4 Acellular Tissue Engineering Products
  • 5.6 Tissue Engineering: Development Pipeline, 2016-2026
    • 5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
    • 5.6.2 Tissue Engineering for Skin
    • 5.6.3 Tissue Engineering for Liver Diseases
    • 5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
    • 5.6.4 Tissue Engineering for Cardiovascular Disease
    • 5.6.5 Tissue Engineering for Eye Diseases
  • 5.7 Future Prospects for Organ Transplantation and Tissue Engineering
  • 5.8 Tissue Engineered Products Market: Drivers and Restraints 2016-2026

6. Gene Therapies: Leading Applications, 2016-2026

  • 6.1 The Global Market for Gene Therapies, 2014 and 2015
  • 6.2 Gene Therapies: Global Market Forecast 2016-2026
  • 6.3 Currently Available Gene Therapy Products
    • 6.3.1 Gendicine (Benda Pharmaceutical)
    • 6.3.2 Oncorine (Shanghai Sunway Biotech)
    • 6.3.3 Neovasculgen (Human Stem Cells Institute)
      • 6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2016-2026
    • 6.3.4 Glybera (UniQure)
      • 6.3.4.1 Glybera: Sales Forecast 2016-2026
      • 6.4.1.4 IMLYGIC (talimogene laherparepvec) - (Amgen)
        • 6.4.1.4.1 Clinical Trials and Development Efforts for IMLYGIC
        • 6.4.1.4.2 Talimogene Laherparepvec (IMLYGIC) - Sales Forecast 2016-2026
  • 6.4 Development Pipeline For Gene Therapies, 2016-2026
    • 6.4.1 Late-Stage Pipeline Gene Therapies, 2015
      • 6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) - (AnGes MG/Vical)
      • 6.4.1.2 ProstAtak (AdV-tk) - (Advantagene)
      • 6.4.1.3 Trinam (taberminogene vadenovec) - (Ark Therapeutics)
      • 6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
      • 6.4.1.5 CG0070 (Cold Genesys)
    • 6.4.2 Gene Therapy for Use in the Treatment of Diabetes
    • 6.4.3 Gene Therapy Directed At Oncology Indications
    • 6.4.4 Gene Therapy Directed at Neurological Diseases
    • 6.4.5 Gene Therapy Directed at Tackling Haemophilia B
  • 6.5 Gene Therapy Market: Drivers and Restraints 2016-2026

7. Leading National Markets for Translational Regenerative Medicine, 2016-2026

  • 7.1 The Translational Regenerative Medicine Market by Region
    • 7.1.1 The Global Distribution of Translational Regenerative Medicine in 2014 and 2015
  • 7.2 Leading National Markets: Forecast 2016-2026
    • 7.2.1 Changing Market Shares By Region, 2016-2026
  • 7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2016-2026
  • 7.4 United States: The Largest Translational Regenerative Medicine Market
    • 7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
    • 7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2016-2026
    • 7.4.3 The Regulatory Framework for Regenerative Medicine in the US
    • 7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
    • 7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
  • 7.5 Europe: A Fragmented Regenerative Medicine Market
    • 7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
    • 7.5.2 European Regenerative Medicine Market: Market Forecast 2016-2026
    • 7.5.3 Europe's Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
    • 7.5.4 Regulation of Regenerative Medicine in the European Union
    • 7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe
    • 7.5.5.1 Regulation of Stem Cell Research in the UK
    • 7.5.6 Russia: Rising Interest in Regenerative Medicine Research
  • 7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
    • 7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
    • 7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2016-2026
    • 7.6.3 Australia: Encouraging Translational Regenerative Medicine
    • 7.6.4 China: Encouraging Stem Cell R&D
      • 7.6.4.1 Government Intervention into TRM Research in China
      • 7.6.4.2 Regulation of Stem Cell Research in China
      • 7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
      • 7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
    • 7.6.5 Japan: Difficulty in Translating Research into Commercialisation
      • 7.6.5.1 Research Funding: A Major Determinant of Growth in Japan's Regenerative Medicine
      • 7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan
      • 7.6.5.3 Regulation of Regenerative Medicine in Japan
      • 7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan
    • 7.6.6 India: An Emerging Market for Regenerative Medicine
      • 7.6.6.1 Efforts in Stem Cell Research in India
      • 7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
    • 7.6.7 South Korea: First to Approve Stem Cell Treatments
      • 7.6.7.1 A Regeneration In South Korea's Stem Cell Research Efforts
  • 7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming
    • 7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2016-2026

8. The Leading Companies in the the Translational Regenerative Medicine Market, 2016-2026

  • 8.1 Translational Regenerative Medicine: A Hotbed for Innovation
  • 8.2 Alphatec Spine
    • 8.2.1 Alphatec Spine: Financial and Performance Analysis, 2009-2014
    • 8.2.2 Alphatec Spine's Shifting Focus from Regenerative Medicine to Medical Devices
  • 8.3 Anterogen
    • 8.3.1 Anterogen: Pipeline Analysis, 2015
  • 8.4 Athersys
    • 8.4.1 Athersys: Financial and Performance Analysis, 2010-2014
    • 8.4.2 Athersys: Pipeline Analysis, 2015
    • 8.4.2.1 MultiStem Technology - Potential Treatment for a Range of Diseases
  • 8.5 Avita Medical
    • 8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015
    • 8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015
    • 8.5.3 Avita Medical: Pipeline Analysis, 2015
  • 8.6 AxoGen
    • 8.6.1 AxoGen: Historical Financial and Performance Analysis, 2010-2014
    • 8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015
    • 8.6.3 AxoGen: Pipeline Analysis, 2015
  • 8.7 Medipost
    • 8.7.1 Medipost: Historical Financial and Performance Analysis, 2010-2014
    • 8.7.2 Medipost: Regenerative Medicine Portfolio, 2015
    • 8.7.3 Medipost: Pipeline Analysis, 2015
  • 8.8 Mesoblast
    • 8.8.1 Mesoblast Product Portfolio, 2015
    • 8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015
    • 8.8.3 Mesoblast: Pipeline Analysis, 2015
      • 8.8.3.1 NeoFuse
      • 8.8.3.2 Chondrogen
      • 8.8.3.3 Prochymal / TEMCELL
      • 8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
  • 8.9 NuVasive
    • 8.9.1 NuVasive Product Portfolio, 2015
    • 8.9.2 NuVasive: Historical Financial and Performance Analysis, 2009-2013
    • 8.9.3 NuVasive: Pipeline Analysis, 2015
  • 8.10 Ocata Therapeutics
    • 8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2009-2014
    • 8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015
    • 8.10.2.1 Retinal Pigment Epithelial Cell Therapy
    • 8.10.3 Ocata's Other Therapeutic Platforms
  • 8.11 Organogenesis
    • 8.11.1 Organogenesis RM Portfolio, 2015
    • 8.11.2 Organogenesis: Pipeline Analysis, 2015
  • 8.12 Osiris Therapeutics
    • 8.12.1 Osiris Therapeutics: RM Portfolio, 2015
    • 8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2010-2014
    • 8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015
  • 8.13 Pharmicell
    • 8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2010-2014
    • 8.13.2 Pharmicell: Pipeline Analysis, 2015
  • 8.14 Regenerys
    • 8.14.1 Regenerys: RM Portfolio, 2015
    • 8.14.2 Regenerys: Pipeline Analysis, 2015
  • 8.15 TiGenix
    • 8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2014
    • 8.15.2 TiGenix: Pipeline Analysis, 2015
  • 8.16 UniQure
    • 8.16.1 UniQure: Pipeline Analysis, 2015
    • 8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)

9. Qualitative Analysis of the Translational Regenerative Medicine Market, 2015

  • 9.1 Market Factors Influencing the Translational Regenerative Medicine Market
  • 9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2016-2026
  • 9.3 Strengths
    • 9.3.1 Improvements in Regulatory Frameworks
    • 9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
    • 9.3.3 Strong Support from Governments in Multiple Regions
    • 9.3.4 Increasing Ease of Product Commercialisation and Market Access
  • 9.4 Weaknesses
    • 9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
    • 9.4.2 Lack of Funding from Venture Capital
    • 9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
    • 9.4.4 Successful Commercialisation of TRM Products Requires New Business Models
  • 9.5 Opportunities
    • 9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
    • 9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
    • 9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
  • 9.6 Threats
    • 9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine
    • 9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
    • 9.6.3 Rate of Scientific Progress - A Major Determinant of TRM Market Growth
    • 9.6.4 Restraints on Reimbursement May Slow Growth
  • 9.7 Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2016-2026
    • 9.7.1 Threat of New Entrants
    • 9.7.2 Threat of Substitutes
    • 9.7.3 Power of Suppliers
    • 9.7.4 Power of Buyers
    • 9.6.5 Rivalry among Competitors

10. Research Interviews

  • 10.1 Interview with Dr Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies
    • 10.1.1 Naïve State Stem Cells Could Significantly Impact the Regenerative Medicine Market
    • 10.1.2 On Relationships between Big Pharma and Smaller Biotech Companies in the Translational Regenerative Market
    • 10.1.3 Growth of Minerva Biotechnologies
    • 10.1.4 Possible New Commercial Applications for Regenerative Medicine
    • 10.1.5 Translational Regenerative Medicine in Emerging Markets
    • 10.1.6 iPS Cells - The Future of Stem Cell Therapies?
    • 10.1.7 On Drivers and Restraints in the Translational Regenarative Medicine Market in 2016
  • 10.2 Interview with Dr Yael Margolin, CEO of Gamida Cell Ltd.
    • 10.2.1 Progress of NiCord in the Blood Cancer Indication
    • 10.2.2 On Drivers and Restraints in the Blood Cancer Market in 2015
    • 10.2.3 Growth of Gamida Cell Ltd.

11. Conclusion

  • 11.1 Overview of Current Market Conditions and Market Forecast, 2014-2026
  • 11.2 Leading Regenerative Medicine Segments in 2014 and 2015
  • 11.3 Leading Regions in the Translational Regenerative Medicine Market in 2014 And 2015
  • 11.4 Future Outlook for the Various Sectors within TRM, 2016-2026
  • 11.5 R&D Pipeline Products Crucial to Future Market Growth
  • 11.6 What Does the Future Hold for Regenerative Medicine?

12. Glossary

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2014-2020 (Altered Data)
  • Table 1.2 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2020-2026 (Altered Data)
  • Table 2.1 European Union Definitions of Regenerative Medicine Products, 2015
  • Table 2.2 Potency and Source of Stem Cells, 2016
  • Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2016
  • Table 2.4 Major Types Of Stem Cells and Their Properties, 2016
  • Table 2.5 Terminology For Stem Cell Donor-Types, 2016
  • Table 2.6 Clinical Trial Phases, 2016
  • Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2014 and 2015
  • Table 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2014-2020
  • Table 3.3 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2020-2026
  • Table 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2020, 2020-2026 and 2014-2026
  • Table 3.5 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014, 2020 and 2026
  • Table 3.6 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014, 2020 and 2026
  • Table 4.1 Selected Stem Cell Products Currently Available On The Market, 2015
  • Table 4.2 Stages of Osteogenesis, 2015
  • Table 4.3 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.4 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.5 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 4.6 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
  • Table 4.7 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.8 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.9 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.10 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.11 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
  • Table 5.1 Selected Tissue Engineering Products Currently Available on the Market, 2015
  • Table 5.2 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.3 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.4 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.5 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.6 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.7 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.8 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 5.9 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 5.10 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2015
  • Table 6.1 Currently Available Gene Therapy Products, 2015
  • Table 6.2 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 6.3 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 6.4 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 6.5 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 6.6 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 6.7 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 6.8 Amgen: Gene Therapy Clinical Trials, 2015
  • Table 6.9 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2014-2026
  • Table 6.10 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2014-2026
  • Table 6.11 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
  • Table 6.12 Advantegene: Gene Therapy Clinical Trials, 2015
  • Table 6.13 Spark Therapeutics: Gene Therapy Clinical Trials, 2015
  • Table 6.14 Recent Developments in Gene Therapy for Use in Diabetes
  • Table 6.15 Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2015
  • Table 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) and Market Share (%) by Region, 2014 and 2015
  • Table 7.2 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2014-2020
  • Table 7.3 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2020-2026
  • Table 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2020, 2020-2026, 2014-2026
  • Table 7.5 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2014, 2020 and 2026
  • Table 7.6 US Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014, 2020 and 2026
  • Table 7.7 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.8 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.9 European Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014, 2020 and 2026
  • Table 7.10 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.11 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.12 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2026
  • Table 7.13 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 7.15 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2026
  • Table 7.16 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 7.17 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 8.1 Alphatec Spine: Historical Sales ($m) and Operating Profit / Loss ($m), 2009-2014
  • Table 8.2 Alphatec Spine: Regenerative Medicine Clinical Trials, 2015
  • Table 8.3 Anterogen: Regenerative Medicine Clinical Trials, 2015
  • Table 8.4 Athersys: Historical Sales ($m) 2010-2014
  • Table 8.5 Athersys: Historical Expenditure and Losses ($m) 2010-2014
  • Table 8.6 Athersys: Regenerative Medicine Clinical Trials, 2015
  • Table 8.7 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2015
  • Table 8.8 Avita Medical: Regenerative Medicine Clinical Trials, 2015
  • Table 8.9 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2014
  • Table 8.10 AxoGen: Regenerative Medicine Clinical Trials, 2015
  • Table 8.11 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2010-2014
  • Table 8.12 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2010-2014
  • Table 8.13 Medipost: Regenerative Medicine Clinical Trials, 2015
  • Table 8.14 Mesoblast: Historical Sales ($m, AUD m), 2010-2015
  • Table 8.15 Mesoblast: Regenerative Medicine Clinical Trials, 2015
  • Table 8.16 NuVasive: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2009-2014
  • Table 8.17 NuVasive: Regenerative Medicine Clinical Trials, 2015
  • Table 8.18 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2014
  • Table 8.19 Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2015
  • Table 8.20 Organogenesis: Regenerative Medicine Clinical Trials, 2015
  • Table 8.21 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2014
  • Table 8.22 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015
  • Table 8.23 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014
  • Table 8.24 Regenerys: Regenerative Medicine Clinical Trials, 2015
  • Table 8.25 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2011-2014
  • Table 8.26 TiGenix: Regenerative Medicine Clinical Trials, 2015
  • Table 8.27 UniQure: Regenerative Medicine Clinical Trials, 2015
  • Table 8.28 Vericel: Historical Sales ($m and AGR%), 2011-2014
  • Table 8.29 Vericel: Sales by Product ($m) and Revenue Share (%), 2013-2014
  • Table 8.30 Vericel Corporation: Regenerative Medicine Clinical Trials, 2015
  • Table 9.1 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2016-2026
  • Table 11.1 Global Translational Regenerative Medicine: Market Forecast ($m, CAGR%), 2014, 2018, 2022, 2026
  • Table 11.2 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2014
  • Table 11.3 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Region, 2014, 2020 and 2026
  • Table 11.4 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2015, 2020 and 2026
  • Table 11.5 Global Translational Regenerative Medicine Market: Products In Late Stage Development, 2015

List of Figures

  • Figure 1.1 Global Translational Regenerative Medicine Market: Submarkets, 2016
  • Figure 2.1 Brief History of Stem Cell Research, 1900-2015
  • Figure 2.2 Examples of FDA-Approved Tissue Engineering Products
  • Figure 2.3 Brief History of Tissue Engineering, 1900-2015
  • Figure 2.4 Brief History of Gene Therapy, 1970-2015
  • Figure 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014 and 2015
  • Figure 3.2 The Gene Therapy Market: Revenue ($m), 2014 and 2015
  • Figure 3.3 The Global Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2020
  • Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2020-2026
  • Figure 3.6 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2026
  • Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014, 202 0 and 2026
  • Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014
  • Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2020
  • Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2026
  • Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 4.5 Stem Cell Therapies: Drivers and Restraints, 2016-2026
  • Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.4 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 5.5 Tissue Engineered Therapy Products: Drivers and Restraints, 2016-2026
  • Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.3 Glybera Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.4 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2014-2026
  • Figure 6.5 Gene Therapy Products: Market Drivers and Restraints, 2016-2026
  • Figure 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) by Region, 2014 and 2015
  • Figure 7.2 Asia-Pacific, Europe, US, and 'Rest of the World' Translational Regenerative Medicine Market: Market Forecast ($m), 2014-2026
  • Figure 7.3 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2020
  • Figure 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2020-2026
  • Figure 7.5 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2026
  • Figure 7.6 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2014
  • Figure 7.7 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2020
  • Figure 7.8 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2026
  • Figure 7.9 US Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026
  • Figure 7.10 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 7.11 European Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026
  • Figure 7.12 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 7.13 Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026
  • Figure 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 7.15 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026
  • Figure 8.1 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2009-2014
  • Figure 8.2 Athersys: Historical Sales ($m) 2010-2014
  • Figure 8.3 Athersys: Historical Revenue, Expenditure and Losses ($m) 2010-2014
  • Figure 8.4 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2014
  • Figure 8.5 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2014
  • Figure 8.6 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014
  • Figure 8.7 Medipost: Revenue Share by Business Area (%), 2012
  • Figure 8.8 Medipost: Revenue Share by Business Area (%), 2013
  • Figure 8.9 Medipost: Revenue Share by Business Area (%), 2014
  • Figure 8.10 Mesoblast: Historical Sales ($m, AUD m), 2011-2014
  • Figure 8.11 NuVasive: Historical Sales and Net Income (Profits and Losses) ($m), 2009-2014
  • Figure 8.12 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2014
  • Figure 8.13 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2014
  • Figure 8.14 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2010-2014
  • Figure 8.15 TiGenix: Historical Sales ($m) and Net Income ($m), 2011-2014
  • Figure 8.16 Vericel: Historical Sales ($m), 2011-2014 (Limited Scale)
  • Figure 8.17 Vericel: Historical Sales ($m), 2011-2014 (Full Scale)
  • Figure 8.18 Vericel: Revenue Contribution by Product (%) 2014
  • Figure 9.1 Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2016
  • Figure 11.1 Global Translational Regenerative Medicine: Market Forecast ($m), 2014, 2020 and 2026
  • Figure 11.2 Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014
  • Figure 11.3 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2014-2026

Companies Listed

  • Advanced BioHealing
  • Advanced Tissue Sciences
  • Advantagene
  • AlloSource
  • AlphaTec Spine
  • Amedica
  • Amgen
  • Amorcyte
  • Amorepacific Group
  • AnGes MG
  • Angioblast Systems
  • Anika Therapeutics
  • Anterogen
  • Apceth
  • Arcarios B.V
  • Ark Therapeutics
  • Athersys Inc
  • Avita Medical
  • AxoGen
  • Baxter
  • Beike Biotechnology
  • Benda Pharmaceutical
  • BioD
  • Bioheart
  • BioMed Realty Trust, Inc
  • BioSante Pharmaceuticals
  • BioTime
  • BioTissue AG
  • BioVex Inc
  • Blackstone Medical
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • California Stem Cell Inc
  • Capricor
  • Cardio3BioSciences
  • Celgene
  • Cell Targeting
  • CellCo Tec
  • Cellerant Therapeutics
  • Cephalon
  • Ceregene
  • CHA Biotech
  • Chiesi Farmaceutici
  • Cipla
  • Co.don AG
  • Cold Genesys
  • Cook Biotech Inc
  • Cytomedix
  • Cytori Therapeutics
  • Daiichi Sankyo
  • DePuy Mitek (Johnson & Johnson)
  • FibroCell Science
  • Gamida Cell Ltd
  • Genzyme Corporation (Sanofi)
  • Histogenics
  • Humacyte
  • Human Stem Cell Institute
  • Insulete Inc
  • Interxon Corporation
  • ISTO Technologies
  • Janssen Biotech Inc
  • Japan Tissue Engineering Co
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Kinetic Concept Inc
  • LecTec Corporation
  • Lincoln Park Capital
  • Lonza
  • MacroCure
  • Medipost
  • Medtronic
  • Mesoblast
  • Mitsubishi Tanabe
  • Myriad Genetics
  • Neostem
  • Neuralstem
  • Nippon Zoki Pharmaceuticals
  • NuVasive
  • Ocata Therapeutics
  • OncoCyte
  • Organovo
  • Orphan Biovitrum AB (Sobi)
  • Orthofix
  • Orteq Ltd.
  • Osiris Therapeutics
  • Oxford BioMedica
  • Parcell Laboratories
  • Pfizer
  • Pharmicell
  • Regenerys
  • Reliance Life Sciences
  • ReNeuron
  • RTI Surgical
  • Rusnano Corporation
  • Sangamo Biosciences
  • Sanofi
  • Shanghai Sunway Biotech
  • Shenzhen Sibiono GeneTech
  • Shire
  • Singapore General Hospital
  • Skye Orthobiologics
  • Smith & Nephewbv
  • Sobi Partners
  • Spark Therapeutics
  • StemCells Inc.
  • Stempeutics Research
  • Stratatech Corporation
  • TCA Cellular Therapy
  • Tengion Inc
  • Teva Pharmaceuticals
  • TiGenix
  • UniQure
  • U.S. Stem Cell Inc.
  • Vericel Corporation
  • Viacyte Inc
  • Vital Therapies
  • WKD Holding Oy
  • Xcellerex
  • Xenetic Biosciences
  • Zimmer

Organisations Mentioned in the Report

  • Arthritis Research UK
  • Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China]
  • Australian Regenerative Medicine Institute
  • Australian Sports Anti-Doping Authority (ASADA)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • British Heart Foundation [UK]
  • California Institute of Regenerative Medicine (CIRM)
  • Cambridge Stem Cell Biology Institute [UK]
  • Case Western Reserve University
  • Catalan Institution for Research and Advanced Studies
  • Center for Biologics Evaluation and Research (CBER) [US]
  • CHA General Hospital [Korea]
  • Cryocenter Saint Petersburg
  • Drugs Controller General of India (DCGI)
  • European Group for Blood and Marrow Transplantation (EBMT)
  • European Medicines Agency
  • Food and Drugs Agency (FDA) [US]
  • Haute Autorité de santé [France]
  • Heriot-Watt University
  • Human Fertilisation and Embryology Authority (HFEA)
  • Institute of Biomedical Research and Innovation Hospital [Japan]
  • International Society for Stem Cell Research (ISSCR)
  • Karolinska Institute [Sweden]
  • Massachusetts General Hospital (MGH)
  • Mayo Clinic [US]
  • Medical Research Council [UK]
  • Ministry of Food and Drug Safety, MFDS) [Korea]
  • Ministry of Health, Labour and Welfare (MHLW) [Japan]
  • Ministry of Science and Technology [China]
  • Moorfields Eye Hospital
  • National Tissue Engineering Center (NTEC) [China]
  • New York Blood Center
  • Riken Center for Developmental Biology
  • RUSH University Medical Center [US]
  • Russian Ministry of Healthcare and Social Development
  • Scottish Centre for Regenerative Medicine
  • St. Jude's Children Research Hospital
  • State Food and Drug Administration (SFDA) [China]
  • SUNY Upstate Medical University
  • The Genetico Center [Russia]
  • The StemGen Organisation
  • Therapeutics Goods Administration (TGA) [Australia]
  • UH San Diego Sanford Stem Cell Clinical Center
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Universitat Autònoma de Barcelona [Spain]
  • University College London
  • University of Edinburgh MRC Centre for Regenerative Medicine [UK]
  • University of Massachusetts (UMass) Memorial Hospital
  • University of Modena Centre for Regenerative Medicine [Italy]
  • University of Wisconsin
  • US National Institute of Health
  • Wake Forest Institute
  • Wellcome Trust
  • World Health Organization
  • Yale School of Medicine
Back to Top